4 stories mentioning GDRX
Every FINWIRES story that references GDRX, newest first.
GoodRx (GDRX) said Wednesday it launched GoodRx Companion, a $14.99-a-month subscription that provides access to generic medications, online care visits, and other healthcare services.The company said the new product expands its subscription strategy as clients are facing tighter insurance restrictions and rising out-of-pocket healthcare costs.Price: $2.82, Change: $+0.04, Percent Change: +1.26%
GoodRx Holdings (GDRX) reported Q1 adjusted earnings late Wednesday of $0.07 per diluted share, down from $0.09 a year earlier.Analysts polled by FactSet expected $0.07.Revenue in the three months ended March 31 fell to $194 million from $203 million a year earlier.Analysts surveyed by FactSet expected $185.4 million.The company expects full-year revenue of $765 million to $785 million.Analysts polled by FactSet expect $764.8 million.GoodRx shares rose 2.1% in after-hours trading.
Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index down 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) was fractionally higher.In corporate news, GSK (GSK) said Wednesday it has completed its $950 million acquisition of 35Pharma, adding an experimental pulmonary hypertension therapy to its respiratory, immunology and inflammation pipeline. GSK shares were down 2.1%.Janux Therapeutics (JANX) lacks near-term stock-moving catalysts after it came under pressure following mixed results from the phase 1a trial of JANX007 in 5L metastatic prostate cancer, UBS said in a report. UBS downgraded the stock to neutral from buy and cut its price target to $15 from $57. Janux shares fell 1.1%.GoodRx (GDRX) shares climbed up 4.3% after the firm said Wednesday it is offering Novo Nordisk's (NVO) Wegovy HD 7.2 mg injectable weight loss drug to eligible self-pay patients. Novo shares rose 3.7%.Immutep (IMMP) shares surged 73% after it said the US Food and Drug Administration has granted orphan drug designation to eftilagimod alfa to treat soft tissue sarcoma, a rare cancer.
Health care stocks were lower Wednesday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 0.9%.The iShares Biotechnology ETF (IBB) decreased 0.4%.In corporate news, Janux Therapeutics (JANX) lacks near-term stock-moving catalysts after it came under pressure following mixed results from the phase 1a trial of JANX007 in 5L metastatic prostate cancer, UBS said in a report. UBS downgraded the stock to neutral from buy and cut its price target to $15 from $57. Janux shares fell 2.9%.GoodRx (GDRX) shares climbed up 3.8% after the firm said Wednesday it is offering Novo Nordisk's (NVO) Wegovy HD 7.2 mg injectable weight loss drug to eligible self-pay patients. Novo shares rose 2.2%.Immutep (IMMP) shares doubled after the firm said the US Food and Drug Administration has granted orphan drug designation to eftilagimod alfa to treat soft tissue sarcoma, a rare cancer.